Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

VOLUNTARY ANNOUNCEMENT

INNOVENT'S PARTNER OLLIN BIOSCIENCES AND ITS NEXT-GENERATION MEDICINES FOR PATIENTS WITH VISION-THREATENING EYE DISEASES TO BE ACQUIRED

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that its partner Ollin Biosciences, Inc. ("**Ollin**") has entered into a definitive agreement to be acquired by Johnson & Johnson (NYSE: JNJ). Ollin's lead program OLN324 (Innovent R&D code: IBI324) was discovered by Innovent and out-licensed to Ollin.

For additional information of the transaction, including financial details, please refer to the press releases issued by Johnson & Johnson and Ollin.

Ollin was founded in 2023 to identify and accelerate the development of next-generation therapies in ophthalmology. Its lead program OLN324, a Phase 3 investigational bispecific antibody designed to target VEGF and Ang2 and optimized for molecular size and potency, is being developed for wet age-related macular degeneration ("**wAMD**") and diabetic macular edema ("**DME**"), two serious retinal diseases affecting more than 40 million people worldwide and among the leading causes of vision loss. With its differentiated design and the data generated to date, OLN324 has the potential to deliver more effective reduction of retinal fluid and allow more time between treatments. Recently Ollin has initiated patient recruitment for global Phase 3 trials of OLN324 for these two indications.

Over the past several years, the Company has collaborated closely with Ollin's expert team to advance OLN324/IBI324 toward Phase 3 development. Retinal vascular diseases affect millions of patients worldwide, and our shared goal is to bring forward this candidate as a meaningful new treatment option. The Company is delighted by this milestone for our partner and gratified that the drug candidate's potential for stronger, more sustained disease control has been recognized by a leading global pharmaceutical partner. Innovent remains fully committed to advancing this program for patients living with retinal vascular diseases, together with our collaborators.

The closing of the transaction is expected to occur by the end of 2026, subject to applicable regulatory approvals and other customary closing conditions.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
November 16, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Ms. Qian Zhang as Executive Director, Mr. Ronald Hao Xi Ede as Non-executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.